Evidence map›Paper›PMID 38022832›Full record

ArticleInternational journal of chronic obstructive pulmonary disease2023

Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK.

Kieran J Rothnie, Beade Numbere, Steven Gelwicks, Yifei Lu, Raj Sharma, Chris Compton, Afisi S Ismaila, Jennifer K Quint

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kieran J RothnieValue Evidence and Outcomes, R&D Global Medical, GSK, London, UK.ORCID 0000-0003-4279-1624
Beade NumbereValue Evidence and Outcomes, R&D Global Medical, GSK, London, UK.
Steven GelwicksValue Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, USA.
Yifei LuValue Evidence and Outcomes, R&D Global Medical, GSK, London, UK.ORCID 0000-0001-8907-4898
Raj SharmaGlobal Medical, GSK, London, UK.
Chris ComptonGlobal Medical, GSK, London, UK.ORCID 0000-0002-7564-5343
Afisi S IsmailaValue Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, USA.ORCID 0000-0002-2876-8308
Jennifer K QuintNational Heart and Lung Institute, Imperial College London, London, UK.ORCID 0000-0003-0149-4869

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged ≥35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.

Indexed as

Pulmonary Disease, Chronic ObstructiveAgedDisease ProgressionFemaleForced Expiratory VolumeHumansMaleRetrospective StudiesRisk FactorsSeverity of Illness IndexUnited KingdomCOPDCPRDexacerbationGOLD A/Brisk factorUK

Identifiers

PMID38022832
PMCPMC10676117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.